JPMorgan analyst Chris Schott raised the firm’s price target on Gilead (GILD) to $145 from $135 and keeps an Overweight rating on the shares. The firm left its large cap biopharma estimates largely unchanged but adjusted price targets on a move to December 2026 from December 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD: